Strategic partnerships Tap into Touchlight's growing collaboration network in 2026 with SVF Vaccines and NEB to position your company as a complementary partner for enzymatic DNA production, vaccine development, and cell-free dbDNA synthesis capabilities.

Clinical pipeline Leverage Touchlight's dbDNA platform and multiple client products in the clinic to present opportunities in pre-clinical and clinical-stage collaborations, potentially accelerating timelines for gene therapy, mRNA, and DNA vaccine programs.

Enzymatic DNA leadership Position your offerings around Touchlight’s patented cell-free DNA manufacturing as a scalable alternative to plasmid DNA, highlighting speed, cost efficiency, and sustainability to meet rising demand in genetic medicine production.

Vaccine and oncology focus Target opportunities related to hepatitis B/D vaccine development and personalized cancer vaccines, given ongoing partnerships and upcoming scale initiatives, to offer manufacturing support, process optimization, or analytical services.

Facility recognition Capitalize on a facility recognized by ISPE FOYA for Innovation to establish credibility in quality, compliance, and GMP manufacturing for potential clients seeking high-standard DNA production for regulatory submissions.